TY - JOUR AU - Mezőlaki, Noémi AU - Baltás, Eszter AU - Ócsai, Henriette AU - Varga, Anita AU - Korom, Irma AU - Varga, Erika AU - Németh, István Balázs AU - Kis, Erika AU - Varga, János AU - Kocsis, Ádám László AU - Gyulai, Rolland Péter AU - Bukva, Mátyás AU - Kemény, Lajos AU - Oláh, Judit Magdolna TI - Tumour regression predicts better response to interferon therapy in melanoma patients. a retrospective single centre study. TS - a retrospective single centre study. JF - MELANOMA RESEARCH J2 - MELANOMA RES VL - 34 PY - 2024 IS - 1 SP - 54 EP - 62 PG - 9 SN - 0960-8931 DO - 10.1097/CMR.0000000000000935 UR - https://m2.mtmt.hu/api/publication/34523817 ID - 34523817 AB - We hypothesise that regression may have an impact on the effectiveness of adjuvant IFN therapy, based on its role in the host immune response. Our purpose is to investigate regression and ulceration as prognostic factors in case of interferon-alpha (IFN)-treated melanoma patients. We followed 357 IFN-treated melanoma patients retrospectively, investigating progression-free survival (PFS) and overall survival (OS) depending on the presence of ulceration and regression. A Kaplan-Meier analysis was performed, and we used a Cox regression analysis to relate risk factors. The survival function of the Cox regression was used to measure the effect of regression and ulceration on PFS and OS depending on the Breslow thickness (T1-T4) of the primary tumour. Regression was significantly positively related to PFS ( P = 0.0018, HR = 0.352) and OS ( P = 0.0112, HR = 0.380), while ulceration showed a negative effect (PFS: P = 0.0001, HR = 2.629; OS: P = 0.0003, HR = 2.388). They influence survival independently. The most favourable outcome was measured in the regressed/non-ulcerated group, whereas the worse was in the non-regressed/ulcerated one. Of risk factors, Breslow thickness is the most significant predictor. The efficacy of regression is regardless of Breslow thickness, though the more favourable the impact of regression was in the thicker primary lesions. Our results indicate that regression is associated with a more favourable outcome for IFN-treated melanoma patients, whereas ulceration shows an inverse relation. Further studies are needed to analyse the survival benefit of regression in relation to innovative immune checkpoint inhibitors. LA - English DB - MTMT ER - TY - JOUR AU - Kelemen, Gyöngyi AU - Együd, Zsófia AU - Dobi, Ágnes AU - Varga, Linda AU - Kószó, Renáta Lilla AU - Borzási, Emőke AU - Paczona, Viktor Róbert AU - Végváry, Zoltán AU - Borzák, Ferenc AU - Fodor, Emese AU - Ócsai, Henriette AU - Baltás, Eszter AU - Oláh, Judit Magdolna AU - Hideghéty, Katalin TI - Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma JF - ANTICANCER RESEARCH J2 - ANTICANCER RES VL - 44 PY - 2024 IS - 1 SP - 205 EP - 212 PG - 8 SN - 0250-7005 DO - 10.21873/anticanres.16803 UR - https://m2.mtmt.hu/api/publication/34509121 ID - 34509121 LA - English DB - MTMT ER - TY - JOUR AU - Ónodi-Nagy, Katinka AU - Csányi, Ildikó AU - Ócsai, Henriette AU - Belső, Nóra AU - Kemény, Lajos AU - Gyulai, Rolland Péter AU - Oláh, Judit Magdolna AU - Csörgő Sándorné Bata, Zsuzsanna AU - Baltás, Eszter TI - Immun-kapcsolt polymyositis és thrombotikus komplikációk adjuváns pembrolizumab kezelés kapcsán JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 99 PY - 2023 IS - 6 SP - 438 SN - 0006-7768 UR - https://m2.mtmt.hu/api/publication/34513904 ID - 34513904 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Hánis, Csilla AU - Csányi, Ildikó AU - Ócsai, Henriette AU - Németh, István Balázs AU - Bende, Balázs AU - Besenyei, Zsuzsanna AU - Hideghéty, Katalin AU - Kemény, Lajos AU - Gyulai, Rolland Péter AU - Oláh, Judit Magdolna AU - Baltás, Eszter TI - Sarcoid-like reakciók előfordulása metasztatikus melanoma miatt immunterápiával kezelt betegnél JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 99 PY - 2023 IS - 6 SP - 438 SN - 0006-7768 UR - https://m2.mtmt.hu/api/publication/34513890 ID - 34513890 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Csányi, Ildikó AU - Hánis, Csilla AU - Ócsai, Henriette AU - Kemény, Lajos AU - Gyulai, Rolland Péter AU - Oláh, Judit Magdolna AU - Baltás, Eszter TI - Metasztatikus melanomás betegek kórlefolyása az immunterápia leállítását követően: egycentrumos retrospektív vizsgálat JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 99 PY - 2023 IS - 6 SP - 424 SN - 0006-7768 UR - https://m2.mtmt.hu/api/publication/34513594 ID - 34513594 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Paszt, Attila AU - Simonka, Zsolt AU - Budai, Krisztina AU - Horváth, Zoltán AU - Erdos, Marton AU - Vas, Márton Árpád AU - Ottlakán, Aurél AU - Nyári, Tibor András AU - Szepes, Zoltán AU - Uhercsák, Gabriella AU - Maráz, Anikó AU - Torday, László AU - Tiszlavicz, László AU - Oláh, Judit Magdolna AU - Lázár, György ifj ED - Ottlakán, Aurél ED - Papp, Andras ED - Toth, Dezso ED - Wu, Aiwen TI - Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy T2 - Surgical and Oncological Updates in the Management of Gastric Cancer: the Role of Neoadjuvant Therapy and Minimally Invasive Surgery PB - Frontiers Media S.A. CY - Lausanne SN - 9782832539521 T3 - Frontiers Research Topics, ISSN 1664-8714 PY - 2023 SP - 56 EP - 68 PG - 13 UR - https://m2.mtmt.hu/api/publication/34426094 ID - 34426094 N1 - Másodközlés, eredeti közlés rekordja: 33729458 LA - English DB - MTMT ER - TY - JOUR AU - Rózsa, Petra AU - Ágoston, Dóra AU - Szederkényi, Edit AU - Ócsai, Henriette AU - Baltás, Eszter AU - Vass, Gábor AU - Kemény, Lajos AU - Oláh, Judit Magdolna AU - Kis, Erika TI - Immunszupprimált betegek multiplex bőrdaganatainak elektrokemoterápiás kezelése [Electrochemotherapy for multiple cutaneous tumors in immunosuppressed patients] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 164 PY - 2023 IS - 37 SP - 1462 EP - 1468 PG - 7 SN - 0030-6002 DO - 10.1556/650.2023.32852 UR - https://m2.mtmt.hu/api/publication/34340896 ID - 34340896 AB - Introduction: The risk of cutaneous malignancies is significantly higher in immunosuppressed patients compared to the general population. These high-risk skin tumors tend to be aggressive, multiplex, rapidly growing lesions. It is common to see local recurrence after surgical excision. Multiplex tumors are difficult to treat, especially in the head/ neck region.Objective: Amongst the standard treatment options, electrochemotherapy can be a suitable option. Our aim was to evaluate the efficacy of electrochemotherapy in immunocompromised patients.Method: In 9 immunosuppressed patients, 118 (average: 13, n = 5-27) non-melanoma skin tumors were treated with electrochemotherapy with intravenous administration of bleomycin, according to the ESOPE criteria.Results: The median follow-up was 15 months. 6 months after the treatment, the objective response rate was 96%. We observed complete response in 88%, partial response in 8% and progressive disease in 2% of the treated lesions. In 2%, the response was not evaluable.Conclusion: In immunocompromised patients, electrochemotherapy is an effective and safe therapeutic option for non-melanoma skin tumors. In order to provide more ideal management for this special sub-group, prevention, multidisciplinary approach and optimized immunosuppressive therapy is essential. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Varga, Linda AU - Besenyi, Zsuzsanna AU - Paczona, Viktor Róbert AU - Farkas, István AU - Urbán, Szabolcs AU - Sipka, Gábor AU - Pávics, László AU - Varga, Zoltán AU - Fodor, Emese AU - Hideghéty, Katalin AU - Oláh, Judit Magdolna AU - Bajory, Zoltán AU - Maráz, Anikó TI - Prostate-specific membrane antigen-based imaging for stereotactic irradiation of low-volume progressive prostate cancer: a single-center experience JF - FRONTIERS IN ONCOLOGY J2 - FRONT ONCOL VL - 13 PY - 2023 PG - 11 SN - 2234-943X DO - 10.3389/fonc.2023.1166665 UR - https://m2.mtmt.hu/api/publication/34093322 ID - 34093322 N1 - Department of Oncotherapy, University of Szeged, Szeged, Hungary Department of Nuclear Medicine, University of Szeged, Szeged, Hungary Department of Urology, University of Szeged, Szeged, Hungary Export Date: 28 October 2023 Correspondence Address: Varga, L.; Department of Oncotherapy, Hungary; email: drvargalinda@gmail.com Correspondence Address: Besenyi, Z.; Department of Nuclear Medicine, Hungary; email: besenyi.zsuzsanna@med.u-szeged.hu Chemicals/CAS: abiraterone, 154229-19-3; docetaxel, 114977-28-5; enzalutamide, 915087-33-1 Manufacturers: GE Healthcare, United States Funding text 1: The authors express their sincere gratitude to the Institute of Isotopes Co. Ltd. for the scientific cooperation and valuable advice as well as comments. LA - English DB - MTMT ER - TY - JOUR AU - Pál, Margit AU - Vetró, Éva AU - Nagy, Nikoletta AU - Nagy, Dóra AU - Ferdinandyné Horváth, Emese AU - Bokor, Barbara Anna AU - Varga, Anita AU - Seres, László AU - Oláh, Judit Magdolna AU - Piffkó, József AU - Széll, Márta TI - Whole-Exome Sequencing Identified Two Novel Pathogenic Mutations in the PTCH1 Gene in BCNS JF - CURRENT ISSUES IN MOLECULAR BIOLOGY J2 - CURR ISSUES MOL BIOL VL - 45 PY - 2023 IS - 7 SP - 5293 EP - 5304 PG - 12 SN - 1467-3037 DO - 10.3390/cimb45070336 UR - https://m2.mtmt.hu/api/publication/34035935 ID - 34035935 AB - Basal cell nevus syndrome (BCNS, OMIM 109400) is a familial cancer syndrome characterized by the development of numerous basal cell cancers and various other developmental abnormalities, including epidermal cysts of the skin, calcified dural folds, keratocysts of the jaw, palmar and plantar pits, ovarian fibromas, medulloblastomas, lymphomesenteric cysts, and fetal rhabdomyomas. BCNS shows autosomal dominant inheritance and is caused by mutations in the patched 1 (PTCH1) gene and the suppressor of the fused homolog (SUFU) gene. In a few cases, variants of patched 2 (PTCH2) have been found in patients who met the criteria for BCNS. In an investigation of 11 Hungarian families who fulfilled the diagnostic criteria for BCNS, whole-exome sequencing (WES) and multiplex ligation-dependent probe amplification (MLPA) identified two novel pathogenic variants (c.2994C>A; p.Cys998Ter and c.814_818del; p.Asn272SerfsTer11), one recently identified variant (c.1737_1745del p.Val580_Val582del), and three recurrent disease-causing variants of the PTCH1 gene with a diagnosis rate of 63.6%. Disease-causing variants were not found for the SUFU and PTCH2 genes. These applied methods could not fully elucidate the genetic background of all the BCNS cases that we investigated. To uncover the missing heritability of BCNS, whole-genome sequencing or an epigenetic approach might be considered in the future. LA - English DB - MTMT ER - TY - JOUR AU - Csoma, Zsanett AU - Ábrahám, Rita AU - Meszes, Angéla AU - Dalmády, Szandra AU - Tajti, Zsanett AU - Széll, Márta AU - Tálosi, Gyula AU - Szabó, Miklós AU - Orvos, Hajnalka AU - Oláh, Judit Magdolna AU - Tóth-Molnár, Edit TI - Gyermekbőrgyógyászati kutatások a szegedi Bőrgyógyászati és Allergológiai Klinikán 2004-2023 között [Paediatric dermatological research at the Department of Dermatology and Allergology of the University of Szeged between 2004-2023] JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 99 PY - 2023 IS - 2 SP - 133 EP - 138 PG - 6 SN - 0006-7768 DO - 10.7188/bvsz.2023.99.2.8 UR - https://m2.mtmt.hu/api/publication/33929072 ID - 33929072 LA - Hungarian DB - MTMT ER -